These great businesses have been money machines for investors over the long run.
News & Analysis: Exelixis
These companies have products, products, and more products to keep revenue flowing.
Exelixis has vastly outperformed bluebird bio on the market of late, but will this trend continue?
EXEL earnings call for the period ending March 31, 2020.
Key clinical trial results this quarter will determine the better buy.
Investors are excited about the biotech's positive news from a key late-stage clinical study.
Any significant decline in these great companies should be viewed as a gift to investors.
New combination trials bring hope for patients and investors.
Cheap and ready to outperform, this under-the-radar biotech stock could be a winner.
CRISPR Therapeutics and Exelixis could be excellent long-term picks for your portfolio.